Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/255
| Subject | Predicate | Object | Context |
|---|---|---|---|
| dailymed-drugs:255 | rdf:type | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:255 | rdf:type | dailymed-instance:drugs | lld:dailymed |
| dailymed-drugs:255 | rdfs:label | LIDEX (Cream) | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:dosage | LIDEX Cream is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted. | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:descripti... | LIDEX (fluocinonide) Cream 0.05% is intended for topical administration. The active component is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6��,11��,16��)-. It has the following chemical structure: LIDEX Cream contains fluocinonide 0.5 mg/g in FAPG cream, a specially formulated cream base consisting of citric acid, 1,2,6-hexanetriol, polyethylene glycol 8000, propylene glycol and stearyl alcohol. This white cream vehicle is greaseless, non-staining, anhydrous and completely water miscible. The base provides emollient and hydrophylic properties. In this formulation, the active ingredient is totally in solution. | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:clinicalP... | Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.<br/>Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses . Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile. | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:activeIng... | dailymed-ingredient:fluocin... | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:contraind... | Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:supply | LIDEX (fluocinonide) Cream 0.05% is supplied in 15 g Tube���NDC 99207-511-13 30 g Tube���NDC 99207-511-14 60 g Tube���NDC 99207-511-17 120 g Tube���NDC 99207-511-22 Store at room temperature. Avoid excessive heat, above 40��C (104��F). | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:genericDr... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:activeMoi... | dailymed-ingredient:fluocin... | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:inactiveI... | dailymed-ingredient:citric_... | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:inactiveI... | dailymed-ingredient:propyle... | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:inactiveI... | dailymed-ingredient:polyeth... | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:inactiveI... | dailymed-ingredient:stearyl... | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:inactiveI... | dailymed-ingredient:1,2,6-h... | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:overdosag... | Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects . | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:genericMe... | fluocinonide | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:fullName | LIDEX (Cream) | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:adverseRe... | The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:indicatio... | LIDEX Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:represent... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:routeOfAd... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:255 | dailymed-instance:name | LIDEX | lld:dailymed |
| http://www4.wiwiss.fu-berli... | dailymed-instance:producesD... | dailymed-drugs:255 | lld:dailymed |